» Articles » PMID: 3663788

Early Pharmacokinetics and Clinical Effects of Oral D-amphetamine in Normal Subjects

Overview
Journal Biol Psychiatry
Publisher Elsevier
Specialty Psychiatry
Date 1987 Nov 1
PMID 3663788
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Seven normal subjects received 0.25 mg/kg D-amphetamine orally, both after an overnight fast and again after a standard breakfast. Plasma levels, subjective and cardiovascular effects, and observer-rated activation were assessed hourly for 5 hr. Food did not affect amphetamine levels. Plasma levels peaked at 2-3 hr. Maximum cardiovascular effects generally occurred at 1 hr, whereas maximum behavioral and subjective effects occurred at 2 hr. Subjective and behavioral effects declined thereafter, in spite of substantial amphetamine levels. A separate group of 8 subjects received 0.5 mg/kg D-amphetamine orally. Plasma levels, subjective and cardiovascular effects, and activation ratings were assessed hourly for 4 hr. Maximum plasma levels were approximately twice those seen in the first group. In this case, plasma levels peaked at 3-4 hr; blood pressure and subjective and behavioral effects were all maximal at 2-3 hr and were declining by 4 hr, in spite of stable or rising plasma levels.

Citing Articles

The effects of caffeine and d-amphetamine on spatial span task in healthy participants.

Kassim F, Lim J, Slawik S, Gaus K, Peters B, Lee J PLoS One. 2023; 18(7):e0287538.

PMID: 37440493 PMC: 10343048. DOI: 10.1371/journal.pone.0287538.


Dexamphetamine widens temporal and spatial binding windows in healthy participants.

Kassim F, Lahooti S, Keay E, Iyyalol R, Rodger J, Albrecht M J Psychiatry Neurosci. 2023; 48(2):E90-E98.

PMID: 36918195 PMC: 10019325. DOI: 10.1503/jpn.220149.


Caloric state modulates locomotion, heart rate and motor neuron responses to acute administration of d-amphetamine in zebrafish larvae.

Bansal P, Roitman M, Jung E Physiol Behav. 2023; 264:114144.

PMID: 36889488 PMC: 10070120. DOI: 10.1016/j.physbeh.2023.114144.


The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance.

Higgins G, Silenieks L Curr Top Behav Neurosci. 2022; 57:321-362.

PMID: 35606638 DOI: 10.1007/7854_2022_341.


Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls.

Gautam C, Sharma J, Singla M, Tiwana I, Singh H touchREV Endocrinol. 2022; 17(1):33-36.

PMID: 35118444 PMC: 8320008. DOI: 10.17925/EE.2021.17.1.33.